B. Braun Announces FDA Approval of OTC Wound Management Gel

B. Braun has announced its Prontosan Wound Management Gel with PHMB (Polyhexanide) has received 510(k) FDA for over-the-counter use.

 

Prontosan is used for cleaning wounds as well as moistening and lubricating absorbent wound dressings.

 

The ready-to-use gel contains PHMB and Betaine, the surfactant for the cleansing and moistening of wounds.

 

"Effective wound care management no longer needs to be limited to within healthcare facility walls," said Mike Kelly, director of marketing, infection control products for B. Braun Medical, according to a news release. "The 510(k) clearance for OTC use of ProntosanWound Management Gel advances B. Braun's commitment to infection prevention, helping to provide solutions that positively impact patients' care — in a physician's office, acute care setting or in a patient's home."

 

Read the B. Braun news release about Prontosan.

 

Read more about B. Braun:

 

- Aesculap Implant Systems, a B. Braun Company, Launches New Patient Education Website

 

- B. Braun Medical Production Facility in Switzerland Receives FDA Approval

 

- B. Braun Announces Availability of Large Volume Heparin Infusion Solutions

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers